The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.

The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

Of the big oncology deals since 2016, there are still plenty that could go either way.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.